布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病的临床效果分析

Clinical Effect Analysis of Budesonide Combined with Ipratropium Bromide in Treatment of Chronic Obstructive Pulmonary Disease

目的:探讨布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病的临床效果。方法:选取2021年1月—2022年12月东台市富安镇富东卫生院收治的慢性阻塞性肺疾病患者202例作为研究对象,应用奇偶数法分为两组,各101例。对照组采用布地奈德治疗,观察组在对照组基础上采用异丙托溴铵治疗。比较两组肺功能、炎性因子水平、不良反应发生情况。结果:治疗前,两组第1秒用力呼气容积占预计值百分比、用力肺活量、残气量比较,差异无统计学意义(P>0.05);治疗后,两组第1秒用力呼气容积占预计值百分比、用力肺活量高于治疗前,且观察组高于对照组,两组残气量低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前,两组C反应蛋白、降钙素原、白细胞介素-6水平比较,差异无统计学意义(P>0.05);治疗后,两组C反应蛋白、降钙素原、白细胞介素-6水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:布地奈德联合异丙托溴铵治疗慢性阻塞性肺疾病的临床效果显著,可提高患者肺功能,改善炎性症状,且药物安全性较高。

Objective:To explore the clinical effect of budesonide combined with ipratropium bromide in treatment of chronic obstructive pulmonary disease.Methods:From January 2021 to December 2022,202 patients with chronic obstructive pulmonary disease admitted to Dongtai City Fuan Town Fudong Health Center were selected as the study subjects.They were divided into two groups using the parity number method,with 101 patients in each group.The control group was treated with budesonide and the observation group was treated with ipratropium bromide on the basis of the control group.Pulmonary function,levels of inflammatory factors and adverse reactions were compared between the two groups.Results:Before treatment,there was no significant difference between the two groups in terms of the percentage of forced expiratory volume in 1 second to the predicted value,forced vital capacity,and residual volume(P>0.05).After treatment,the percentage of forced expiratory volume in 1 second to the predicted value and forced vital capacity in the two groups were higher than those before treatment,and these indexes in the observation group were higher than those in the control group,while the residual volume in the two groups was lower than that before treatment,and this index in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in the levels of C-reactive protein,procalcitonin and interleukin-6 between the two groups(P>0.05).After treatment,the levels of C-reactive protein,procalcitonin and interleukin-6 in the two groups were lower than those before treatment,and the levels in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Budesonide combined with ipratropium bromide has significant clinical effect in the treatment of chronic obstructive pulmonary disease,and can improve pulmonary function and inflammatory symptoms,and the drug safety is high.